Treatment
Bortezomib clinical trials
We’re tracking 73 recruiting studies that include Bortezomib, each written for real people, not researchers, below.
Recruiting studies
- NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07008638RecruitingPhase 1/Phase 2
Study of bortezomib plus CPX-351 for newly diagnosed TP53-mutated AML
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT06933277Recruiting
Study of selinexor, bortezomib, and dexamethasone for multiple myeloma
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
FlorenceAges 18 years+ - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
BrusselsAges 18–69 - NCT06464991RecruitingPhase 3
Eque-cel for Lenalidomide-Refractory Multiple Myeloma
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
BeijingAges 18–75 - NCT05979363RecruitingPhase 2
CAR-T cell therapy for plasma cell leukemia patients
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
TianjinAges 18–75 - NCT06627309Recruiting
Rapid blood protein response and remission in AL amyloidosis
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
Beijing, Beijing MunicipalityAges 18–99 - NCT06390319RecruitingPhase 2
Adding dasatinib or venetoclax for children with T-cell leukemia or lymphoma
This trial tests whether adding either dasatinib or venetoclax to standard chemotherapy can improve outcomes for children aged 1 to 18 with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. It compares the effects of these added drugs to help doctors find better treatment options.
San Diego, CaliforniaAges 1–18 - NCT06192979Recruiting
First-line treatment for AL amyloidosis with t(11;14)
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
Beijing, Beijing MunicipalityAges Any age - NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Mobile, AlabamaAges 18 years+ - NCT06142396RecruitingEarly Phase 1
Dara-CyBorD for New Multiple Myeloma with Kidney Failure
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
Augusta, GeorgiaAges 18–80 - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Phoenix, ArizonaAges Up to 1 year - NCT05736419RecruitingPhase 2
Immune-suppressing treatment before stem cell transplant for blood disorders
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
Basking Ridge, New JerseyAges 2–50 - NCT05695508RecruitingPhase 2
Tested treatment for multiple myeloma after standard care
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
BerlinAges 18–70 - NCT05561387RecruitingPhase 3
Drug combinations for newly diagnosed myeloma without transplant
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
Anchorage, AlaskaAges Any age - NCT05558319RecruitingPhase 3
New myeloma study comparing three treatment plans before transplant
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
Alcalá de Henares, MadridAges 18–65 - NCT04268199RecruitingPhase 2
At-home chemotherapy teaching for people with myeloma
This study tests whether people with symptomatic myeloma can safely learn to give themselves chemotherapy at home. It aims to make treatment easier while tracking safety and whether treatment is done correctly.
Calgary, AlbertaAges 18 years+ - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
La Jolla, CaliforniaAges 18 years+ - NCT04566328RecruitingPhase 3
Newly diagnosed multiple myeloma test of combination therapy
This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.
Anchorage, AlaskaAges 18 years+ - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT03590171RecruitingPhase 2
Study for children with relapsed high-risk ALL
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
Clayton, VictoriaAges Up to 17 years - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+
Common questions
- Are there clinical trials studying Bortezomib?
- Yes. Clin2 currently lists 73 recruiting studies that include Bortezomib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Bortezomib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Bortezomib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Bortezomib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.